David Schwartz
Cardiovascular Disease · Plano, TXNPI 1629065156
Payments from drug & device makers
Across 196 payments — averaging $481.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bristol Myers Squibb$71K
- E.r. Squibb & Sons, L.L.C.$19K
- AbbVie$800
- Astellas Pharma US Inc$406
- Novartis$398
- Amgen$376
- plus $2K from 25 others
What the payments were for
- Consulting fees$80020%
- Food & beverage$3,10779%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bristol Myers Squibb | 8 | $71,499 |
| E.r. Squibb & Sons, L.L.C. | 8 | $19,025 |
| AbbVie | 1 | $800 |
| Astellas Pharma US Inc | 24 | $406 |
| Novartis | 21 | $398 |
| Amgen | 28 | $376 |
| Amarin Pharma, Inc. | 23 | $330 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $210 |
| Sanofi-aventis U.S. LLC | 17 | $200 |
| Merck | 8 | $153 |
| Pfizer | 8 | $143 |
| Boston Scientific | 3 | $115 |
| Novo Nordisk | 6 | $106 |
| Regeneron Healthcare Solutions, Inc. | 6 | $97 |
| Johnson & Johnson | 5 | $77 |
| Esperion Therapeutics, Inc. | 5 | $70 |
| Philips North America LLC | 2 | $56 |
| Intuitive Surgical | 1 | $55 |
| Boehringer Ingelheim | 3 | $50 |
| Itamar Medical Inc | 2 | $31 |
| Regeneron | 1 | $26 |
| AstraZeneca | 1 | $22 |
| GE HealthCare | 1 | $21 |
| Gilead | 1 | $20 |
| Abbott | 1 | $19 |
| Bayer | 1 | $17 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $17 |
| Teleflex LLC | 1 | $13 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
| Chiesi USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rinvoq$800
How this compares
$94,389 in reported general payments places this provider in the 90th percentile of 1,515 cardiovascular disease providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 172 | $183,602 |
| XareltoRivaroxaban | 70 | $76,045 |
| Repatha SureclickEvolocumab | 74 | $74,116 |
| EntrestoSacubitril/Valsartan | 53 | $64,037 |
| JardianceEmpagliflozin | 48 | $59,283 |
| MultaqDronedarone Hcl | 30 | $41,435 |
| Praluent PenAlirocumab | 25 | $20,741 |
| OzempicSemaglutide | 12 | $14,020 |
| Rosuvastatin Calcium | 400 | $5,287 |
| Metoprolol Succinate | 232 | $3,192 |
| Ranolazine ErRanolazine | 22 | $2,637 |
| Atorvastatin Calcium | 247 | $2,398 |
| Telmisartan-HydrochlorothiazidTelmisartan/Hydrochlorothiazid | 44 | $2,356 |
| Candesartan-HydrochlorothiazidCandesartan/Hydrochlorothiazid | 16 | $2,188 |
| Nebivolol Hcl | 34 | $2,072 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $143 | $183,602172 claims |
| Johnson & JohnsonXarelto | $77 | $76,04570 claims |
| NovartisEntresto | $398 | $64,03753 claims |
| Boehringer IngelheimJardiance | $50 | $59,28348 claims |
| Sanofi-aventis U.S. LLCMultaq | $200 | $41,43530 claims |
| Novo NordiskOzempic | $106 | $14,02012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in Plano
- David BrownPlano$2.7M
- Sahil BakshiPlano$628K
- Ramin Farzaneh-FarDallas$17.1M
- Jeffrey GladdenDallas$15.8M
- Ann NavarDallas$14.5M
- David BrabhamAmarillo$11.5M
- Justin GrodinDallas$6.2M
- Christie BallantyneHouston$4.6M
- Syed NaqviHouston$3.6M
- Faisal WahidMcKinney$3.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.